Method of treating chronic inflammatory disease

Inhibiting MEK1/2 signaling with (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide addresses multiple inflammation pathways, effectively treating chronic inflammatory diseases by downregulating ETS2 target genes.

WO2026240830A1PCT designated stage Publication Date: 2026-11-19PASITHEA THERAPEUTICS CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/016801
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-02-26
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current therapies for chronic inflammatory diseases, such as Crohn's disease and lupus, are ineffective due to the lack of understanding of the disease mechanism and redundancy in inflammation pathways, leading to high failure rates in drug development.

Method used

Administering (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or its pharmaceutically acceptable salts, which inhibit MEK1/2 signaling and downregulate ETS2 target genes, thereby addressing multiple inflammation pathways.

Benefits of technology

This approach effectively reduces chronic inflammation by blocking ETS2 signaling and downregulating its target genes, providing a therapeutic benefit for immune-mediated inflammatory diseases like Inflammatory Bowel Disease, Primary Sclerosing Cholangitis, and Ankylosing Spondylitis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026016801_19112026_PF_FP_ABST
    Figure US2026016801_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are methods of treating chronic inflammation or inflammatory disease, comprising administering a therapeutically effective amount of (5R,6S)-10, 11 -difluoro- 12-((2 - fluoro-4-iodophenyl)amino)-5, 6-dihydroxy -4,5,6, 7 -tetrahydro- 1H- spiro[benzo[b][l,5,4]oxafhiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), or a tablet formulation of Compound 1.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No. 14763-021-228METHOD OF TREATING CHRONIC INFLAMMATORY DISEASECROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application No.63 / 805,235, filed May 13, 2025, the disclosure of which is incorporated by reference herein in its entirety.FIELD

[0002] Provided herein are methods of treating chronic inflammation or inflammatory disease, comprising administering a therapeutically effective amount of (5R,6S)-10,ll-difluoro-12-((2 -fluoro-4-iodophenyl)amino)-5,6-dihydroxy -4,5,6, 7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), or a tablet formulation of Compound 1.

[0003] In certain embodiments, provided herein is (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), for use in methods of treating chronic inflammation or inflammatory disease.BACKGROUND

[0004] Nearly 5% of humans live with an autoimmune or inflammatory disease. These heterogeneous conditions, ranging from Crohn’s disease and ulcerative colitis (collectively inflammatory bowel disease (IBD)) to psoriasis and lupus, all require better therapies, but only 10% of drugs entering clinical development ever become approved treatments. (See, e.g., Stankey, et al. Nature 630, 447-456 (2024); Dowden, et al., Nat. Rev.Drug Discov. 18, 495-496 (2019)). This failure is due in part to the fact that the etiology of chronic inflammation is based partly on the various inflammation inducing molecules and the multitude of inflammation mediating and sensitizing molecules that appear to elicit inflammation via redundant mechanisms. Chronic inflammation derives from prolonged release of inflammatory mediating and sensitizing molecules, such as, e.g., pro-inflammatory cytokines, pro-inflammatory prostaglandins, leukotrienes, histamine, serotonin, neutral proteases, bradykinin, and nitric oxide, in response to an injurious stimulus. However, the disease mechanism is poorly understood. The lack of efficacy and mechanistic understanding is responsible for the high failure rate. Blocking individual cytokines is a common treatment strategy in inflammatory disease (see, e.g., Park, etal., Cell 185, 4259-4279 (2022)), however,1NAI-5010499833vlemerging evidence suggests that targeting several cytokines at once may be a better approach (see, e.g., Feagan, et al., Lancet Gastroenterol. Hepatol. 8, 307-320 (2023)).

[0005] Recently, ETS2 has been identified as a master regulator of inflammatory responses in IBD, and a novel genetic mechanism behind the disease has been uncovered (see, e.g., Stankey, et al. Nature 630, 447-456 (2024); see FIG. 1). A new, potentially effective treatment strategy through MEK inhibition appears promising. The methods and compositions provided herein meet these needs and provide other related advantages.SUMMARY

[0006] Provided herein are methods of treating chronic inflammation or inflammatory disease, comprising administering a therapeutically effective amount of (5R,6S)-10,ll-difluoro-12-((2 -fluoro-4-iodophenyl)amino)-5,6-dihydroxy -4,5,6, 7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), to a patient having chronic inflammation or inflammatory disease.

[0007] Provided herein are methods of treating chronic inflammation or inflammatory disease, comprising administering to a patient having chronic inflammation or chronic inflammatory disease a tablet formulation of Compound 1. Provided herein are methods of treating chronic inflammation or inflammatory disease, comprising administering to a patient having chronic inflammation or chronic inflammatory disease a tablet formulation comprising about 1% to about 10% of (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

[0008] Also, provided herein are methods of blocking ETS2 signalling, the method comprising inhibiting MEK1 / 2 with Compound 1. Provided herein are methods of blocking ETS2 signalling, the method comprising inhibiting MEK1 / 2 with a tablet formulation of Compound 1.

[0009] Also, provided herein are methods of downregulating ETS2 target genes in a patient having chronic inflammatory disease, the method comprising administering to the patient Compound 1. Provided herein are methods of downregulating ETS2 target genes in a patient2NAI-5010499833vlhaving chronic inflammatory disease, the method comprising administering to the patient a tablet formulation of Compound 1.

[0010] Also, provided herein are methods of treating a patient with immune-mediated inflammatory disease, comprising administering a therapeutically effective amount of Compound 1 or a tablet formulation of Compound 1 to the patient having immune-mediated inflammatory disease. In certain embodiments, the immune-mediated inflammatory disease is Inflammatory Bowel Disease (IBD), Primary Sclerosing Cholangitis (PSC), Takayasu Arteritis, or Ankylosing Spondylitis.[OH] Also provided are pharmaceutical compositions formulated for administration by an appropriate route and means containing a therapeutically effective amount of Compound 1 provided herein, and optionally comprising at least one pharmaceutical carrier. In some embodiments, the pharmaceutical compositions provided herein contain the tablet formulations of Compound 1 described herein.

[0012] In one embodiment, the pharmaceutical compositions deliver amounts effective for the treatment of chronic inflammation or an immune-mediated inflammatory disease.

[0013] In one embodiment, provided herein are methods of treating chronic inflammation or an immune-mediated inflammatory disease comprising administering the Compound 1 or pharmaceutical compositions of Compound 1 provided herein. Also provided herein are combination therapies using Compound 1 or pharmaceutical compositions of Compound 1 provided herein, in combination with a therapy, e.g., another pharmaceutical agent with activity against diseases or disorders in which the ETS2 pathway is downregulated, such as chronic inflammation or an immune-mediated inflammatory disease or their symptoms.

[0014] These and other aspects of the subject matter described herein will become evident upon reference to the following detailed description.BRIEF DESCRIPTION OF DRAWINGS

[0015] FIG. 1 provides a schematic diagram showing the MEK1 / 2 pathway and downstream ETS2 blockage.

[0016] FIG. 2 is a bar graph of RNA sequence results which shows read counts for every sample, following read alignment, QC, and expression filtering. Results show more than 5 million read counts for each sample.

[0017] FIG. 3 is a hierarchical cluster dendrogram of all samples. No major outliers were observed. The acronym “PAS” refers to Compound 1, and the acronym “Sei” refers to selumetinib.3NAI-5010499833vl

[0018] FIGS. 4A-4C show: (FIG.4A) Screen Plot of the percentage of explained variances attributable to the indicated principal components from Principal Component Analysis plots of scaled and normalized read counts, coded according to experimental conditions (FIG. 4B) or donor (FIG. 4C). In the plots, “PAS” refers to Compound 1, “Sei” refers to selumetinib, and “D” refers to donor.

[0019] FIGS. 5A-5C show: (FIG. 5A) scaled Gene Set Variance Analysis (GSVA) results for direct targets of MEK1 / 2 (defined as genes significantly downregulated in TPP macrophages following 48h treatment with PD-0325901 / Mirdametinib); (FIG. 5B) scaled GSVA results for genes downregulated following deletion of the ETS2 super-enhancer at chr21q22; and (FIG. 5C) scaled GSVA results for genes downregulated following CRISPR editing of ETS2 in TPP macrophages. Expression data were converted to counts-per-million and quantile normalized before analysis. Scaling was performed by increasing all values relative to the lowest GSVA result for each respective signature.

[0020] FIGS. 6A and 6B show: (FIG. 6A) Gene Set Enrichment Analysis (fGSEA) of differentially-expressed genes between ETS2-edited and unedited inflammatory macrophages (ranked gene list obtained from Stankey, et al. Nature 630, 447-456 (2024); and (FIG. 6B) enrichment plot of significantly downregulated genes in ETS2-edited versus unedited macrophages. In (FIG. 6A), dot size represents P-value and shading denotes normalized enrichment score (NES); “PAS” refers to Compound 1, and “Selu” refers to selumetinib.

[0021] FIG. 7 shows the Gene Set Enrichment Analysis (fGSEA) of differentially-expressed genes between Compound 1 (1 mM) and vehicle control -treated inflammatory macrophages. Results of selected Gene Ontology Biological Pathways shown. Dot size represents P-value and shading denotes normalized enrichment score (NES).

[0022] FIGS. 8A-8L show levels of inflammatory cytokines in the supernatants of TPP macrophages as quantified by LegendPLEX; (FIG. 8A) IL lb; (FIG. 8B) IL6; (FIG. 8C) IL8;(FIG. 8D) IL12p70; (FIG. 8E) IL17A; (FIG. 8F) IL18; (FIG. 8G) IFNa2; (FIG. 8H) IFNg;(FIG. 81) IL 10; (FIG. 8 J) TNFa; (FIG. 8K) MCP1; (FIG. 8L) IL33. Plots show log2 foldchange of cytokine concentrations in the indicated experimental conditions, relative to the levels measured in the vehicle control. “Sei” refers to selumetinib.DETAILED DESCRIPTION

[0023] The details of construction and the arrangement of components set forth in the following description or illustrated in the drawings are intended to describe non-limiting embodiments. Other embodiments and different ways to practice the invention are expressly4NAI-5010499833vlincluded. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having,” “containing”, “involving”, and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

[0024] As used herein, the terms “comprising” and “including” can be used interchangeably. The terms “comprising” and “including” are to be interpreted as specifying the presence of the stated features or components as referred to, but does not preclude the presence or addition of one or more features, or components, or groups thereof. Additionally, the terms “comprising” and “including” are intended to include examples encompassed by the term “consisting of’. Consequently, the term “consisting of’ can be used in place of the terms “comprising” and “including” to provide for more specific embodiments of the invention.

[0025] The term “consisting of’ means that a subject-matter has at least 90%, 95%, 97%, 98% or 99% of the stated features or components of which it consists. In another embodiment the term "consisting of’ excludes from the scope of any succeeding recitation any other features or components, excepting those that are not essential to the technical effect to be achieved.

[0026] As used herein, the term “or” is to be interpreted as an inclusive “or” meaning any one or any combination. Therefore, “A, B or C” means any of the following: “A; B; C; A and B; A and C; B and C; A, B and C”. An exception to this definition will occur only when a combination of elements, functions, steps, or acts are in some way inherently mutually exclusive.1. Definitions

[0027] As used above, and throughout the description of the invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings.

[0028] As used in this application, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.

[0029] “Compound 1” is meant to refer to (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt thereof, including solid forms of the free base and salts thereof. The compound chemically named 10,1 l-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide belongs to a novel class of MEK1 / 2 inhibitors having a macrocyclic scaffold, which has been disclosed in US 9,034,861, which is herein incorporated by reference in its entirety. Solid forms of (5R,6S)-10,l 1-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH- 5NAI-5010499833vlspiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide have been described in International Application No. PCT / US2025 / 010064 (filed January 2, 2025), Chinese priority application No. PCT / CN2024 / 070736 (filed January 5, 2024) and US provisional application No. 63 / 722,522 (filed November 19, 2024). (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide, its corresponding diastereoisomers, and its solid forms have also been disclosed in International Application No. PCT / US2025 / 010070 (filed January 2, 2025) and US provisional application Nos. 63 / 618,167 and 63 / 722,523 (filed January 5, 2024 and November 19, 2024 respectively). All of the abovementioned applications are herein incorporated by reference in their entirety.

[0030] The term “solid form” refers to a crystal form or an amorphous form or a mixture thereof of (5R,6S)-10,l 1 -difluoro- 12-((2-fluoro-4-iodophenyl)amino)-5, 6-dihydroxy-4, 5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt thereof.

[0031] As used herein, and unless otherwise indicated, a chemical compound or composition that is “substantially free” of another chemical compound or composition means that the compound or composition contains, in certain embodiments, less than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% by weight of the other compound or composition.

[0032] As used herein, and unless otherwise specified, a compound that is “substantially chemically pure” is substantially free from other chemical compounds ( / .<?., chemical impurities). In certain embodiments, a compound that is substantially chemically pure contains less than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% of one or more other chemical compounds on a weight basis. The detection of other chemical compounds can be accomplished by any method apparent to a person of ordinary skill in the art, including, but not limited to, methods of chemical analysis, such as, e.g., mass spectrometry analysis, spectroscopic analysis, thermal analysis, elemental combustion analysis, and / or chromatographic analysis.

[0033] As used herein and unless otherwise indicated, the terms “pure” when applied to a chiral compound or “stereoisomer” or “stereomerically pure” means one stereoisomer of a compound disclosed herein that is substantially free of other stereoisomers of that compound. For example, a stereomerically pure compound having one chiral center will be substantially free of the opposite enantiomer of the compound. A stereomerically pure compound having 6NAI-5010499833vltwo chiral centers will be substantially free of other diastereomers of the compound. A typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, or greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound. The compounds disclosed herein have chiral centers and can occur as individual enantiomers or diastereomers, and mixtures thereof. All such isomeric forms are included within the embodiments disclosed herein, including mixtures thereof.

[0034] The use of stereomerically pure forms of such compounds, as well as the use of mixtures of those forms, are encompassed by the embodiments disclosed herein. For example, mixtures comprising equal or unequal amounts of the enantiomers of a particular compound may be used in methods and compositions disclosed herein. These isomers may be asymmetrically synthesized or resolved using standard techniques such as chiral columns or chiral resolving agents. See, e.g., Jacques, J., et al., Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen, S. H., etal., Tetrahedron 33:2725 (1977); Eliel, E. L., Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S. H., Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ, of Notre Dame Press, Notre Dame, IN, 1972).

[0035] As used herein and unless otherwise indicated, the term “prodrug” means a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide an active compound, particularly a compound disclosed herein. Examples of prodrugs include, but are not limited to, derivatives and metabolites of a compound disclosed herein that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. In certain embodiments, prodrugs of compounds with carboxyl functional groups are the lower alkyl esters of the carboxylic acid. The carboxylate esters are conveniently formed by esterifying any of the carboxylic acid moieties present on the molecule. Prodrugs can typically be prepared using well-known methods, such as those described by Burger ’s Medicinal Chemistry and Drug Discovery 6thed. (Donald J. Abraham ed., 2001, Wiley) an Design and Application of Prodrugs (H. Bundgaard ed., 1985, Harwood Academic Publishers Gmfh).7NAI-5010499833vl

[0036] Tautomers” refers to isomeric forms of a compound that are in equilibrium with each other. The concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution. For example, in aqueous solution, pyrazoles may exhibit the following isomeric forms, which are referred to as tautomers of each other:

[0037] Unless otherwise specified, the terms “solvate” and “solvated,” as used herein, refer to a solid form of a substance which contains solvent. The terms “hydrate” and “hydrated” refer to a solvate wherein the solvent comprises water. The terms “solvate” and “solvated,” as used herein, can also refer to a solvate of a salt, co-crystal, or molecular complex. The terms “hydrate” and “hydrated,” as used herein, can also refer to a hydrate of a salt, co-crystal, or molecular complex.

[0038] The term “isotopologue” of a compound described herein refers to a compound that can contain unnatural proportions of atomic isotopes at one or more of the atoms. For example, an isotopologue of Compounds 1 to 4 may be radiolabeled at one more positions with radioactive isotopes, such as for example tritium (3H), and / or carbon-14 (14C), or may be isotopically enriched at one or more positions, such as with deuterium (2H), carbon-13 (13C), oxygen- 18 (18O) and / or nitrogen- 15 (15N). In certain embodiments, a compound described herein can be radiolabeled at one more positions with radioactive isotopes, such as for example tritium (3H), and / or carbon-14 (14C), while also being isotopically enriched at one or more positions, such as with deuterium (2H), carbon-13 (13C), oxygen-18 (18O) and / or nitrogen-15 (15N).

[0039] All isotopic variations of Compounds 1 to 4, whether radioactive or not, are intended to be encompassed within the scope of the embodiments provided herein. In some embodiments, there are provided isotopologues of Compounds 1 to 4, for example, the isotopologues are deuterium, carbon-13, or nitrogen-15 enriched Compounds 1 to 4.

[0040] With regard to the compounds provided herein, when a particular atomic position is designated as having deuterium or “D,” it is understood that the abundance of deuterium at that position is substantially greater than the natural abundance of deuterium, which is about 0.0156%. A position designated as having deuterium typically has a minimum isotopic enrichment factor of, in particular embodiments, at least 100 (1.56% deuterium incorporation),8NAI-5010499833vlat least 500 (7.8% deuterium incorporation), at least 1000 (15.6% deuterium incorporation), at least 2000 (31.2% deuterium incorporation), at least 3000 (46.8% deuterium incorporation), at least 3500 (54.6% deuterium incorporation), at least 4000 (62.4% deuterium incorporation), at least 4500 (70.2% deuterium incorporation), at least 5000 (78% deuterium incorporation), at least 5500 (85.8% deuterium incorporation), at least 6000 (93.6% deuterium incorporation), at least 6089.7 (95% deuterium incorporation), at least 6217.9 (97% deuterium incorporation), at least 6346.2 (99% deuterium incorporation), or at least 6378.2 (99.5% deuterium incorporation) at each designated deuterium atom.

[0041] The isotopic enrichment and isotopic enrichment factor of the compounds provided herein can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.

[0042] The term “treat” means decrease, suppress, attenuate, alleviate, diminish, arrest, or stabilize the development or progression of a disease / disorder (i.e., an autoimmune or inflammatory disease).

[0043] As used herein, and unless otherwise specified, the terms “prevent,” “preventing” and “prevention” refer to the prevention of the onset, recurrence or spread of a disease or disorder, or of one or more symptoms thereof. The terms “prevent,” “preventing” and “prevention” contemplate an action that occurs before a patient begins to suffer from the specified disease or disorder or symptoms thereof, which inhibits or reduces the severity of the disease or disorder.

[0044] As used herein, and unless otherwise indicated, the terms “manage,” “managing” and “management” encompass preventing the recurrence of the specified disease or disorder in a patient who has already suffered from the disease or disorder, or lengthening the time that a patient who has suffered from the disease or disorder remains in remission. The terms encompass modulating the threshold, development or duration of the disease or disorder, or changing the way that a patient responds to the disease or disorder.

[0045] As used herein, and unless otherwise specified, a “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment or management of a disease or disorder, or to delay or minimize one or more symptoms associated with the disease or disorder. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment or management of the disease or disorder. The term “therapeutically effective amount” can encompass an amount that improves overall therapy,9NAI-5010499833vlreduces or avoids symptoms or causes of disease or disorder, or enhances the therapeutic efficacy of another therapeutic agent.

[0046] Unless otherwise specified, the term “composition” as used herein is intended to encompass a product comprising the specified ingredient(s) (and in the specified amount(s), if indicated), as well as any product which results, directly or indirectly, from combination of the specified ingredient(s) in the specified amount(s).

[0047] A “pharmaceutically acceptable excipient, diluent or carrier,” refers to a substance that aids the administration of an active agent to a subject by for example by modifying the stability of an active agent or modifying the absorption by a subject upon administration. A pharmaceutically acceptable excipient typically has no significant adverse toxicological effect on the patient. Examples of pharmaceutically acceptable excipients include, for example bulking agents, buffers, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, fatty acid esters, hydroxy methylcellulose, polyvinyl pyrrolidine, and colors, and the like. One of skill in the art will recognize that other pharmaceutical excipients known in the art are useful in the present invention and include those listed in for example the Handbook of Pharmaceutical Excipients, Rowe R.C., Shesky P.J., and Quinn M.E., 6thEd., The Pharmaceutical Press, RPS Publishing (2009). The terms “bulking agent”, and “buffer” are used in accordance with the plain and ordinary meaning within the art.

[0048] As used herein, “administer” or “administration” refers to the act of physically delivering a substance as it exists outside the body into a subject. Administration includes all forms known in the art for delivering therapeutic agents, including but not limited to oral, topical, mucosal, injections, intradermal, intravenous, intramuscular delivery or other method of physical delivery described herein or known in the art (e.g., implantation of a slow-release device, such as a mini-osmotic pump to a subject; liposomal formulations; buccal; sublingual; palatal; gingival; nasal; vaginal; rectal; intra-arteriole; intraperitoneal; intraventricular; intracranial; or transdermal).

[0049] As used herein, “subject” or “patient” is an animal, typically a mammal, including a human, such as a human patient.

[0050] As used herein, and unless otherwise specified, the terms “about” and “approximately,” when used in connection with doses, amounts, or weight percents of ingredients of a composition or a dosage form, mean a dose, amount, or weight percent that is recognized by one of ordinary skill in the art to provide a pharmacological effect equivalent to that obtained from the specified dose, amount, or weight percent. In certain embodiments, the terms “about” and “approximately,” when used in this context, contemplate a dose, amount, or 10NAI-5010499833vlweight percent within 30%, within 20%, within 15%, within 10%, or within 5%, of the specified dose, amount, or weight percent.

[0051] In certain embodiments, such as those referring to the location of a peak on a XRPD spectrum, “approximately” refers to a value within (e.g., ±) 0.2° 29, 0.1° 29, or 0.05° 29 of the named value. In some embodiments, the value of XRPD peak position may vary by up to ±0.2 degrees 29 while still describing the particular XRPD peak. In one embodiment, the value of XRPD peak position may vary up to ± 0.1 degrees 29. In one embodiment, the value of XRPD peak position may vary up to ± 0.05 degrees 29.

[0052] Unless otherwise specified, to the extent that there is a discrepancy between a depicted chemical structure of a compound provided herein and a chemical name of a compound provided herein, the chemical structure shall control.2. Compounds

[0053] In certain embodiments, provided herein is (5R,6S)-10,ll-difhioro-12-((2-fhioro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide having the following formula:

[0054] In one embodiment, Compound 1 provided herein is a crystalline solid. In one embodiment, Compound 1 provided herein is Form A. In one embodiment, Compound 1 provided herein is Form B. In one embodiment, Compound 1 provided herein is Form C.

[0055] In one embodiment, Compound 1 provided herein is a solid form comprising a free base of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 8.5, 15.1, and 18.3° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 9.2, 12.0, and 17.0° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 20.8, 22.0, 24.1, and 27.4° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 8.5, 9.2, 10.7, 11.6, 12.0, 12.8, 15.1, 17.0, 18.3, 20.8, 22.0, 24.1, and 27.4° 29. In some such embodiments, Compound 1 is solid Form A. In one embodiment, solid Form A is characterized by an XRPD pattern comprising peaks at approximately 8.5, 15.1, and 18.3° 29. In one embodiment, solid Form A is characterized by11NAI-5010499833vlanXRPD pattern comprising peaks at approximately 8.5, 9.2, 10.7, 11.6, 12.0, 12.8, 15.1, 17.0, 18.3, 20.8, 22.0, 24.1, and 27.4° 29. In one embodiment, the solid Form A comprising a free base of Compound 1 is an anhydrate.

[0056] In one embodiment, Compound 1 provided herein is a solid form comprising a free base of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 8.4, 12.5, and 16.9° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 17.6, 17.9, and 18.1° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 20.4, 23.5, and 23.8° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 25.2, 27.1, and 29.2° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 16.9, and 17.9° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 16.9, 17.6, 17.9, and 18.1° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 14.8, 14.9, and 15.3° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 21.9, 23.5, and 23.8° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 8.4, 9.0, 10.3, 11.5, 12.5, 14.8, 14.9, 15.3, 16.9, 17.6, 17.9, 18.1, 19.3, 19.9, 20.4, 21.9, 23.5, 23.8, 24.1, 24.9, 25.2, 25.6, 27.1, 28.5, 28.9, 29.2, 30.3, 31.7, 32.0, 32.4, 32.8, 35.7, and 36.7° 29. In some such embodiments, Compound 1 is solid Form B. In one embodiment, the solid Form B comprising a free base of Compound l isa solvate. In some such embodiments, Compound 1 is solid Form B. In one embodiment, solid Form B is characterized by an XRPD pattern comprising peaks at approximately 8.4, 12.5, and 16.9° 29. In one embodiment, solid Form B is characterized by anXRPD pattern comprising peaks at approximately 8.4, 9.9, 19.3, 11.5, 12.5, 14.8, 14.9, 15.3, 16.9, 17.6, 17.9, 18.1, 19.3, 19.9, 29.4, 21.9, 23.5, 23.8, 24.1, 24.9, 25.2, 25.6, 27.1, 28.5, 28.9, 29.2, 39.3, 31.7, 32.9, 32.4, 32.8, 35.7, and 36.7° 29. In one embodiment, the solid Form B comprising a free base of Compound 1 is an acetonitrile solvate.

[0057] In one embodiment, Compound 1 provided herein is a solid form comprising a free base of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 8.3, 12.6, and 16.6° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 17.4, 18.1, and 18.4° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 29.7, 23.4, and 23.6° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 25.4, 26.9, 27.9, and 29.9° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 16.6, 17.4, 18.1, and 18.4° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 29.7, 21.1, 21.4, and 21.9° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 23.4, 23.6, and 24.1° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 12NAI-5010499833vl24.8, 25.9, 25.4, 25.9, and 26.9° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 27.9 and 28.4° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 29.9, 31.9° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 8.3, 9.1, 19.5, 11.5, 11.7, 12.6, 16.6, 17.4, 18.1, 18.4, 29.7, 21.1, 21.4, 21.9, 23.4, 23.6, 24.1, 24.8, 25.9, 25.4, 25.9, 26.9, 27.9, 28.4, 29.9, 31.9, 31.3, 31.7, and 32.7° 29. In some such embodiments, Compound 1 is solid Form C. In one embodiment, solid Form C is characterized by an XRPD pattern comprising peaks at approximately 8.3, 12.6, and 16.6° 29. In one embodiment, solid Form C is characterized by an XRPD pattern comprising peaks at approximately 8.3, 9.1, 19.5, 11.5, 11.7, 12.6, 16.6, 17.4, 18.1, 18.4, 29.7, 21.1, 21.4, 21.9, 23.4, 23.6, 24.1, 24.8, 25.9, 25.4, 25.9, 26.9, 27.9, 28.4, 29.9, 31.9, 31.3, 31.7, and 32.7° 29. In one embodiment, the solid Form C comprising a free base of Compound 1 is a solvate. In one embodiment, the solid Form C comprising a free base of Compound l is a methanol solvate.

[0058] In certain embodiments, provided herein is Compound 2. In certain embodiments, provided herein is pure Compound 2 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, isotopologue, or prodrug thereof:

[0059] In certain embodiments, provided herein is Compound 3. In certain embodiments, provided herein is pure Compound 3 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, isotopologue, or prodrug thereof:13NAI-5010499833vl

[0060] In certain embodiments, provided herein is Compound 4. In certain embodiments, provided herein is pure Compound 4 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, isotopologue, or prodrug thereof:

[0061] In certain embodiments, the compound disclosed herein (e.g., Compound 1, Compound 2, Compound 3, or Compound 4) is the stereomerically pure compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, isotopologue, or prodrug thereof. In certain embodiments, the compound according to Compound 1 to 4 is the stereomerically pure compound or a pharmaceutically acceptable salt thereof. In certain embodiments, the stereomerically pure compound comprises at least about 80% by weight of the designated stereoisomer and at most about 20% by weight of the other stereoisomer(s), at least about 90% by weight of the designated stereoisomer and at most about 10% by weight of the other stereoisomer(s), at least about 95% by weight of the designated stereoisomer and at most about 5% by weight of the other stereoisomer(s), at least about 96.6% by weight of the designated stereoisomer and at most about 3.4% by weight of the other stereoisomer(s), at least about 97% by weight of the designated stereoisomer and at most about 3% by weight of the other stereoisomer(s), at least about 99% by weight of the designated stereoisomer and at most about 1% by weight of the other stereoisomer(s), or at least about 99.9% by weight of the designated stereoisomer and at most about 0.1% by weight of the other stereoisomer(s). In certain embodiments, the weights are based upon total weight of the compound. Compounds 1 through 4 and their method of preparation have been described in U.S. Provisional Application No. 63 / 722,523, filed November 19, 2024; U.S. Provisional Application No.63 / 618,167, filed January 05, 2024, and International Application Number PCT / US2025 / 010070, filed January 2, 2025, the disclosures of each of which are incorporated by reference herein in their entirety.14NAI-5010499833vl3. Formulations

[0062] In certain embodiments, the formulations provided herein are tablets comprising Compound 1 and a pharmaceutically acceptable excipient. Tablet formulations of Compound 1 have been described in Chinese priority application No. PCT / CN2024 / 133928 (filed November 22, 2024) and US provisional application No. 63 / 744,073 (filed January 10, 2025). All of the abovementioned applications are herein incorporated by reference in their entirety.

[0063] In certain embodiments, the tablet provided herein comprises Compound 1 in about 1% to about 10% by weight based on total weight of the tablet. In certain embodiments, the tablet provided herein comprises Compound 1 in about 2% to about 3% by weight based on total weight of the tablet. In certain embodiments, the tablet provided herein comprises Compound 1 in about 3% to about 4% by weight based on total weight of the tablet. In certain embodiments, the tablet provided herein comprises Compound 1 in about 4% to about 5% by weight based on total weight of the tablet. In certain embodiments, the tablet composition provided herein comprises Compound 1 in about 1%, about 2%, about 3%, about 4%, or about 5% by weight based on total weight of the tablet. In certain embodiments, the tablet provided herein comprises Compound 1 in about 5% by weight based on total weight of the tablet.

[0064] In certain embodiments, the tablet provided herein comprises Compound 1 and one or more excipients selected from a binder, a diluent, a disintegrant, a flow agent, a surfactant, a glidant and a lubricant. In certain embodiments, the tablet provided herein comprises Compound 1 and one or more excipients selected from a diluent, a disintegrant, a glidant, and a lubricant.

[0065] In certain embodiments, the binder is povidone. In certain embodiments, the binder is present in an amount from about 10% to 50% by weight based on total weight of the tablet.

[0066] In certain embodiments, the diluent is microcrystalline cellulose, lactose monohydrate, or pregelatinized starch, mannitol, anhydrous dibasic calcium phosphate, or a mixture thereof. In certain embodiments, the diluent is present in an amount from about 10% to 65% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 10% to 50% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 14% to 45% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 20% to 45% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 30% to 45% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 42% to 46% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in 15NAI-5010499833vlan amount from about 22% to 26% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 13% to 17% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount of about 15%, about 20%, about 23%, about 24%, about 30%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 44.2%, about 44.4%, about 62%, about 63%, about 64%, or about 65% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount of about 15%, about 24%, or about 44.2% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount of about 15%, about 24%, or about 44.4% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount of about 15%, about 24%, or about 44% by weight based on total weight of the tablet. In certain embodiments, the diluent is mannitol, which is present in an amount of about 30% by weight based on total weight of the tablet. In certain embodiments, the diluent is anhydrous dibasic calcium phosphate, which is present in an amount of about 30% by weight based on total weight of the tablet. In certain embodiments, the diluent is microcrystalline cellulose, which is present in an amount of about 44.4% by weight based on total weight of the tablet. In certain embodiments, the diluent is lactose monohydrate, which is present in an amount of about 24% by weight based on total weight of the tablet. In certain embodiments, the diluent is pregelatinized starch, which is present in an amount of about 15% by weight based on total weight of the tablet.

[0067] In certain embodiments, the disintegrant is present in an amount from about 2 to 15% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is present in an amount from about 8 to 12% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is present in an amount from about 5 to 10% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is present in an amount from about 5 to 7% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is present in an amount of about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is present in an amount of about 5% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is present in an amount of about 10% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is croscarmellose sodium, which is present in an amount of about 5% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is crospovidone, which is present in an amount of about 10% by weight based on total weight of the tablet.16NAI-5010499833vl

[0068] In certain embodiments, the flow agent is silicified microcrystalline cellulose. In certain embodiments, the flow agent is present in an amount from about 10% to 50% by weight based on total weight of the tablet.

[0069] In certain embodiments, the surfactant is sodium lauryl sulfate. In certain embodiments, the surfactant is present in an amount from about 1% to 10% by weight based on total weight of the tablet.

[0070] In certain embodiments, the glidant is colloidal silicon dioxide. In certain embodiments, the glidant is present in an amount from about 0.01% to 1% by weight based on total weight of the tablet. In certain embodiments, the glidant is present in an amount from about 0.1% to 0.6% by weight based on total weight of the tablet. In certain embodiments, the glidant is present in an amount from about 0.2% to 0.6% by weight based on total weight of the tablet. In certain embodiments, the glidant is present in an amount from about 0.3% to 0.7% by weight based on total weight of the tablet. In certain embodiments, the glidant is present in an amount from about 0.4% to 0.5% by weight based on total weight of the tablet. In certain embodiments, the glidant is present in an amount of about 0.5% by weight based on total weight of the tablet. In certain embodiments, the glidant is colloidal silicon dioxide, which is present in an amount of about 0.5% by weight based on total weight of the tablet.

[0071] In certain embodiments, the lubricant is magnesium stearate or sodium stearyl fumarate. In certain embodiments, the lubricant is present in an amount from about 0.05% to 5% by weight based on total weight of the tablet. In certain embodiments, the lubricant is present in an amount from about 0.1% to 5% by weight based on total weight of the tablet. In certain embodiments, the lubricant is present in an amount from about 0.1% to 2% by weight based on total weight of the tablet. In certain embodiments, the lubricant is present in an amount from about 0.1% to 1% by weight based on total weight of the tablet. In certain embodiments, the lubricant is present in an amount from about 0.05% to 0.7% by weight based on total weight of the tablet. In certain embodiments, the lubricant is present in an amount of about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5% by weight based on total weight of the tablet. In certain embodiments, the lubricant is present in an amount of about 0.5% by weight based on total weight of the tablet. In certain embodiments, the lubricant is magnesium stearate, which is present in an amount of about 0.1% by weight based on total weight of the tablet. In certain embodiments, the lubricant is magnesium stearate, which is present in an amount of about 0.5% by weight based on total weight of the tablet. In certain embodiments, the lubricant is 17NAI-5010499833vlmagnesium stearate, which is present in an amount of about 1% by weight based on total weight of the tablet. In certain embodiments, the lubricant is sodium stearyl fumarate, which is present in an amount of about 1% by weight based on total weight of the tablet.

[0072] In certain embodiments, the tablet provided herein comprises Compound 1, microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. In certain embodiments, the tablet provided herein comprises Compound 1, mannitol, anhydrous dibasic calcium phosphate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and sodium stearyl fumarate.

[0073] In certain embodiments, the tablet provided herein comprises Compound 1, microcrystalline cellulose, lactose monohydrate, crospovidone, colloidal silicon dioxide, and magnesium stearate. In certain embodiments, the tablet provided herein comprises Compound 1, microcrystalline cellulose, lactose monohydrate, pregelatinized starch, crospovidone, colloidal silicon dioxide, and magnesium stearate.

[0074] In certain embodiments, the tablet provided herein comprises about 1% to about 10% Compound 1, about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, by weight based on total weight of the tablet.

[0075] In certain embodiments, the tablet provided herein comprises about 5% Compound 1, about 44.4% microcrystalline cellulose, about 24% lactose monohydrate, about 15% pregelatinized starch, about 10% crospovidone, about 0.5% colloidal silicon dioxide, and about 0.1% magnesium stearate, where the percentages are by weight based on total weight of the tablet. In some such embodiments, the tablet further comprising 0.5% magnesium stearate. In some such embodiments, the tablet further comprises 0.5% colloidal silicon dioxide.

[0076] In certain embodiments, the tablet provided herein comprises about 5% Compound 1, about 44.4% microcrystalline cellulose, about 24% lactose monohydrate, about 15% pregelatinized starch, about 10% crospovidone, about 1% colloidal silicon dioxide, and about 0.6% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

[0077] In certain embodiments, the tablet provided herein comprises intragranular components and extragranular components. In certain embodiments, the tablet provided herein comprises intragranular components comprising about 5% Compound 1, about 44.4% microcrystalline cellulose, about 24% lactose monohydrate, about 15% pregelatinized starch, about 10% crospovidone; about 0.5% colloidal silicon dioxide, and about 0.1% magnesium 18NAI-5010499833vlstearate; and extragranular components comprising about 0.5% magnesium stearate and about 0.5% colloidal silicon dioxide.

[0078] In certain embodiments, each tablet weighs about 1 mg to about 200 mg. In certain embodiments, each tablet weighs about 1 mg to about 100 mg. In certain embodiments, each tablet weighs about 1 mg to about 80 mg. In certain embodiments, each tablet weighs about 1 mg to about 60 mg. In certain embodiments, each tablet weighs about 1 mg to about 40 mg. In certain embodiments, each tablet weighs about 1 mg to about 20 mg. In certain embodiments, each tablet weighs about 1 mg to about 10 mg. In certain embodiments, each tablet weighs about 1 mg, 1.5 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, or 20 mg. In certain embodiments, each tablet weighs about 1 mg, 3 mg, 4 mg, 5 mg, 10 mg, 20 mg, about 80 mg, or about 200 mg. In certain embodiments, each tablet weighs about 20 mg. In certain embodiments, each tablet weighs about 80 mg. In certain embodiments, each tablet weighs about 200 mg.

[0079] In certain embodiments, each tablet has a diameter of about 1 mm to 10 mm. In certain embodiments, each tablet has a diameter of about 2 mm to 8 mm. In certain embodiments, each tablet has a diameter of about 3 mm to 5 mm. In certain embodiments, each tablet has a diameter of about 1 mm, 2 mm, 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, or about 10 mm. In certain embodiments, each tablet has a diameter of about 3 mm. In certain embodiments, each tablet has a diameter of about 5.5 mm. In certain embodiments, each tablet has a diameter of about 5 mm. In certain embodiments, each tablet has a diameter of about 8 mm.

[0080] In certain embodiments, the tablet comprises a coating. In certain embodiments, the coating is Opadry. In certain embodiments, the coating is Opadry yellow. In certain embodiments, the coating provides a weight gain of about 1 to 5%. In certain embodiments, the coating provides a weight gain of about 2 to 3%. In certain embodiments, the coating provides a weight gain of about 1%, 2%, or 3%. In certain embodiments, the coating provides a weight gain of about 3%.4. Method of Use

[0081] Provided herein is a method of treating chronic inflammation or inflammatory disease comprising administering a therapeutically effective amount of the compounds disclosed herein (e.g., Compound 1, Compound 2, Compound 3, and Compound 4). In one embodiment, provided herein is a method of treating chronic inflammation or inflammatory disease comprising administering a therapeutically effective amount of (5R,6S)-10,ll- 19NAI-5010499833vldifluoro- 12-((2 -fluoro-4-iodophenyl)amino)-5,6-dihydroxy -4,5,6, 7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), to a patient having chronic inflammation or inflammatory disease. In one embodiment, provided herein is Compound 1 provided herein for use in a method of treating chronic inflammation or inflammatory disease, wherein the method comprises administering Compound 1 to a patient having chronic inflammation or inflammatory disease.

[0082] In one embodiment, provided herein is a method of treating chronic inflammation or inflammatory disease, comprising administering to a patient having chronic inflammation or chronic inflammatory disease a tablet formulation comprising Compound 1. In one embodiment, provided herein is a method of treating chronic inflammation or inflammatory disease, wherein the method comprises administering to a patient having chronic inflammation or chronic inflammatory disease a tablet formulation comprising about 1% to about 10% of (5R, 6S)-10, 11 -difluoro- 12-((2 -fluoro-4-iodophenyl)amino)-5,6-dihydroxy -4,5,6, 7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

[0083] In one embodiment, provided herein is a tablet formulation of Compound 1 provided herein for use in a method of treating chronic inflammation or inflammatory disease, wherein the method comprises administering said tablet formulation to a patient. In one embodiment, provided herein is a tablet formulation of Compound 1 provided herein for use in a method of treating chronic inflammation or inflammatory disease, wherein the method comprises administering to a patient having chronic inflammation or chronic inflammatory disease a tablet formulation comprising about 1% to about 10% of (5R,6S)-10, 11 -difluoro- 12-((2-flu oro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.20NAI-5010499833vl

[0084] In one embodiment, provided herein is a method of preventing a chronic inflammation or inflammatory disease, comprising administering a therapeutically effective amount of the compounds disclosed herein (e.g., Compound 1, Compound 2, Compound 3, and Compound 4). In one embodiment, provided herein is a method of preventing a chronic inflammation or inflammatory disease, which comprises administering to a patient a therapeutically effective amount of Compound 1 provided herein. In one embodiment, provided herein is Compound 1 provided herein for use in a method of preventing a chronic inflammation or inflammatory disease, wherein the method comprises administering Compound 1 provided herein to a patient.

[0085] In one embodiment, provided herein is a method of preventing a chronic inflammation or inflammatory disease, which comprises administering to a patient a tablet formulation of Compound 1 provided herein. In one embodiment, provided herein is a tablet formulation of Compound 1 provided herein for use in a method of preventing a chronic inflammation or inflammatory disease, wherein the method comprises administering a tablet formulation of Compound 1 provided herein to a patient.

[0086] In one embodiment, provided herein is a method of managing a chronic inflammation or inflammatory disease, which comprises administering a therapeutically effective amount of the compounds disclosed herein (e.g., Compound 1, Compound 2, Compound 3, and Compound 4). In one embodiment, provided herein is a method of managing a chronic inflammation or inflammatory disease, which comprises administering to a patient a therapeutically effective amount of Compound 1 provided herein. In one embodiment, provided herein is Compound 1 provided herein for use in a method of managing a chronic inflammation or inflammatory disease, wherein the method comprises administering Compound 1 provided herein to a patient.

[0087] In one embodiment, provided herein is a method of managing a chronic inflammation or inflammatory disease, which comprises administering to a patient a tablet formulation of Compound 1 provided herein. In one embodiment, provided herein is a tablet formulation of Compound 1 provided herein for use in a method of managing a chronic inflammation or inflammatory disease, wherein the method comprises administering a tablet formulation of Compound 1 provided herein to a patient.

[0088] In a particular embodiment, the tablet formulation of Compound 1 comprises about 1% to about 10% of (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-di oxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), about 42%21NAI-5010499833vlto about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

[0089] In one embodiment, provided herein is a method of treating a patient with an immune-mediated inflammatory disease, comprising administering a therapeutically effective amount of the compounds disclosed herein (e.g., Compound 1, Compound 2, Compound 3, and Compound 4). In one embodiment, provided herein is a method of treating a patient with an immune-mediated inflammatory disease, comprising administering a therapeutically effective amount of the Compound 1 provided herein to the patient having immune-mediated inflammatory disease. In one embodiment, provided herein is Compound 1 provided herein for use in a method of treating a patient with an immune-mediated inflammatory disease, wherein the method comprises administering Compound 1 provided herein to the patient.

[0090] In one embodiment, provided herein is a method of treating a patient with an immune-mediated inflammatory disease, comprising administering a tablet formulation of Compound 1 provided herein to the patient having an immune-mediated inflammatory disease. In one embodiment, provided herein is a tablet formulation of Compound 1 provided herein for use in a method of treating a patient with an immune-mediated inflammatory disease, wherein the method comprises administering a tablet formulation of Compound 1 provided herein to the patient.

[0091] In one embodiment, provided herein is a method of treating a patient with an immune-mediated inflammatory disease, comprising administering a therapeutically effective amount of the Compound 1 provided herein or the tablet formulation of Compound 1 provided herein to the patient having immune-mediated inflammatory disease.

[0092] In a particular embodiment, the tablet formulation of Compound 1 comprises about 1% to about 10% of (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-di oxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

[0093] In one embodiment, the methods described herein comprise the step of administering to a patient a therapeutically effective amount of the compounds disclosed herein e.g.,22NAI-5010499833vlCompound 1, Compound 2, Compound 3, and Compound 4), wherein the administration reduces a symptom associated with the chronic inflammation, thereby treating the patient.

[0094] In one embodiment, the methods described herein comprise the step of administering to a patient a therapeutically effective amount of Compound 1 or a tablet formulation of Compound 1 disclosed herein, wherein the administration reduces a symptom associated with the chronic inflammation, thereby treating the patient.

[0095] In one embodiment, chronic inflammation symptoms include, without limitation, edema, hyperemia, erythema, bruising, tenderness, stiffness, swollenness, fever, chills, stuffy nose, stuffy head, breathing problems, fluid retention, blood clots, loss of appetite, increased heart rate, formation of granulomas, fibrinous, pus, non-viscous serous fluid, or ulcer and pain. The actual symptoms associated with a chronic inflammation are well known and can be determined by a person of ordinary skill in the art by taking into account factors, including, without limitation, the location of the inflammation, the cause of the inflammation, the severity of the inflammation, the tissue or organ affected, and the associated disorder.

[0096] In some embodiments, specific patterns of chronic inflammation are seen during particular situations that arise in the body, such as when inflammation occurs on an epithelial surface, or pyogenic bacteria are involved. For example, granulomatous inflammation is an inflammation resulting from the formation of granulomas arising from a limited but diverse number of diseases, including, without limitation, tuberculosis, leprosy, sarcoidosis, and syphilis. Purulent inflammation is an inflammation resulting in a large amount of pus, which consists of neutrophils, dead cells, and fluid. Infection by pyogenic bacteria such as staphylococci is characteristic of this kind of inflammation. Serous inflammation is an inflammation resulting from copious effusion of non-viscous serous fluid, commonly produced by mesothelial cells of serous membranes, but may be derived from blood plasma. Skin blisters exemplify this pattern of inflammation. Ulcerative inflammation is an inflammation resulting from the necrotic loss of tissue from the epithelial surface, exposing lower layers, and forming an ulcer.

[0097] In certain embodiments, a chronic inflammation symptom can be associated with a large, unrelated group of disorders which underlay a variety of diseases and disorders. The immune system is often involved with chronic inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation. Non-immune diseases with etiological origins in chronic inflammatory processes include cancer, atherosclerosis, and ischaemic heart disease. Nonlimiting examples of disorders exhibiting chronic inflammation as a symptom include, without 23NAI-5010499833vllimitation, acne, acid reflux / heartbum, age related macular degeneration (AMD), allergy, allergic rhinitis, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, appendicitis, arteritis, arthritis, asthma, atherosclerosis, autoimmune disorders, balanitis, blepharitis, bronchiolitis, bronchitis, a bullous pemphigoid, bum, bursitis, cancer, cardiac arrest, carditis, celiac disease, cellulitis, cervicitis, cholangitis, cholecystitis, chori oamnionitis, chronic obstructive pulmonary disease (COPD), cirrhosis, colitis, congestive heart failure, conjunctivitis, cyclophosphamide-induced cystitis, cystic fibrosis, cystitis, common cold, dacryoadenitis, dementia, dermatitis, dermatomyositis, diabetes, diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic ulcer, digestive system disease, eczema, emphysema, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibromyalgia, fibrosis, fibrositis, gastritis, gastroenteritis, gingivitis, glomerulonephritis, glossitis, heart disease, heart valve dysfunction, hepatitis, hidradenitis suppurativa, Huntington's disease, hyperlipidemic pancreatitis, hypertension, ileitis, infection, inflammatory bowel disease, inflammatory cardiomegaly, inflammatory neuropathy, insulin resistance, interstitial cystitis, interstitial nephritis, iritis, ischemia, ischemic heart disease, keratitis, keratoconjunctivitis, laryngitis, lupus nephritis, mastitis, mastoiditis, meningitis, metabolic syndrome (syndrome X), a migraine, multiple sclerosis, myelitis, myocarditis, myositis, nephritis, non-alcoholic steatohepatitis, obesity, omphalitis, oophoritis, orchitis, osteochondritis, osteopenia, osteomyelitis, osteoporosis, osteitis, otitis, pancreatitis, Parkinson's disease, parotitis, pelvic inflammatory disease, pemphigus vulgaris, pericarditis, peritonitis, pharyngitis, phlebitis, pleuritis, pneumonitis, polycystic nephritis, proctitis, prostatitis, psoriasis, pulpitis, pyelonephritis, pylephlebitis, renal failure, reperfusion injury, retinitis, rheumatic fever, rhinitis, salpingitis, sarcoidosis, sialadenitis, sinusitis, spastic colon, stenosis, stomatitis, stroke, surgical complication, synovitis, tendonitis, tendinosis, tenosynovitis, thrombophlebitis, tonsillitis, trauma, traumatic brain injury, transplant rejection, trigonitis, tuberculosis, tumor, urethritis, bursitis, uveitis, vaginitis, vasculitis, and vulvitis. See also, U.S. Patent 6,063,768, which is hereby incorporated by reference in its entirety.

[0098] In one embodiment, a chronic inflammation comprises a tissue inflammation. Tissue inflammation is a chronic inflammation that is confined to a particular tissue or organ. In aspect of this embodiment, a tissue inflammation comprises, e.g., a skin inflammation, a muscle inflammation, a tendon inflammation, a ligament inflammation, a bone inflammation, a cartilage inflammation, a lung inflammation, a heart inflammation, a liver inflammation, a pancreatic inflammation, a kidney inflammation, a bladder inflammation, a stomach inflammation, an intestinal inflammation, a neuron inflammation, and a brain inflammation.24NAI-5010499833vl

[0099] In one embodiment, a chronic inflammation comprises a systemic inflammation. Although the processes involved are identical to tissue inflammation, systemic inflammation is not confined to a particular tissue but in fact overwhelms the body, involving the endothelium and other organ systems. When it is due to infection, the term sepsis is applied, with the term “bacteremia” being applied specifically for bacterial sepsis and viremia specifically to viral sepsis. Vasodilation and organ dysfunction are serious problems associated with widespread infection that may lead to septic shock and death.

[0100] In one embodiment, a chronic inflammation comprises an arthritis. Arthritis includes a group of conditions involving damage to the joints of the body due to the inflammation of the synovium including, without limitation osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthropathies like ankylosing spondylitis, reactive arthritis (Reiter's syndrome), psoriatic arthritis, enteropathic arthritis associated with inflammatory bowel disease, Whipple disease and Behcet disease, septic arthritis, gout (also known as gouty arthritis, crystal synovitis, metabolic arthritis), pseudogout (calcium pyrophosphate deposition disease), and Still's disease. Arthritis can affect a single joint (monoarthritis), two to four joints (oligoarthritis) or five or more joints (polyarthritis) and can be either an auto-immune disease or a nonautoimmune disease.

[0101] In one embodiment, a chronic inflammation comprises an autoimmune disorder. Autoimmune diseases can be broadly divided into systemic and organ-specific autoimmune disorders, depending on the principal clinico-pathologic features of each disease. Systemic autoimmune diseases include, without limitation, systemic lupus erythematosus (SLE), Sjogren's syndrome, Scleroderma, rheumatoid arthritis, and polymyositis. Local autoimmune diseases may be endocrinologic (Diabetes Mellitus Type 1, Hashimoto's thyroiditis, Addison's disease etc.), dermatologic (pemphigus vulgaris), hematologic (autoimmune haemolytic anemia), neural (multiple sclerosis) or can involve virtually any circumscribed mass of body tissue. Types of autoimmune disorders include, without limitation, acute disseminated encephalomyelitis (ADEM), Addison's disease, an allergy or sensitivity, amyotrophic lateral sclerosis, anti-phospholipid antibody syndrome (APS), arthritis, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune pancreatitis, bullous pemphigoid, celiac disease, Chagas disease, chronic obstructive pulmonary disease (COPD), diabetes mellitus type 1 (IDDM), endometriosis, fibromyalgia, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's thyroiditis, hidradenitis suppurativa, idiopathic thrombocytopenic purpura, inflammatory bowel disease (IBD), interstitial cystitis, lupus (including discoid lupus erythematosus, drug-induced lupus 25NAI-5010499833vlerythematosus, lupus nephritis, neonatal lupus, subacute cutaneous lupus erythematosus, and systemic lupus erythematosus), morphea, multiple sclerosis (MS), myasthenia gravis, myopathies, narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, primary biliary cirrhosis, recurrent disseminated encephalomyelitis (multiphasic disseminated encephalomyelitis), rheumatic fever, schizophrenia, scleroderma, Sjogren's syndrome, tenosynovitis, vasculitis, and vitiligo. See, e.g., W02006138059A2, which is hereby incorporated by reference in its entirety.

[0102] In another embodiment, a chronic inflammation comprises a myopathy. Myopathies are caused when the immune system inappropriately attacks components of the muscle, leading to inflammation in the muscle. A myopathy includes an inflammatory myopathy and an autoimmune myopathy. Myopathies include, without limitation, dermatomyositis, inclusion body myositis, and polymyositis.

[0103] In another embodiment, a chronic inflammation comprises vasculitis. Vasculitis is a varied group of disorders featuring inflammation of a vessel wall including lymphatic vessels and blood vessels like veins (phlebitis), arteries (arteritis) and capillaries due to leukocyte migration and resultant damage. The inflammation may affect any size blood vessel, anywhere in the body. It may affect either arteries and / or veins. The inflammation may be focal, meaning that it affects a single location within a vessel; or it may be widespread, with areas of inflammation scattered throughout a particular organ or tissue, or even affecting more than one organ system in the body. Vasculitis include, without limitation, Buerger disease (thromboangiitis obliterans), cerebral vasculitis (central nervous system vasculitis), Churg-Strauss arteritis, cryoglobulinemia, essential cryoglobulinemic vasculitis, giant cell (temporal) arteritis, Golfer's vasculitis, Henoch-Schbenlein purpura, hypersensitivity vasculitis (allergic vasculitis), Kawasaki disease, microscopic poly arteritis / poly angiitis, polyarteritis nodosa, polymyalgia rheumatica (PMR), rheumatoid vasculitis, Takayasu arteritis, Wegener's granulomatosis, and vasculitis secondary to connective tissue disorders like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), relapsing polychondritis, Behcet's disease, or other connective tissue disorders, vasculitis secondary to viral infection.

[0104] In another embodiment, a chronic inflammation comprises a skin disorder. Skin disorders include, without limitation, an acne, including acne vulgaris, a bullous pemphigoid, a dermatitis, including atopic dermatitis and chronic actinic dermatitis, an eczema like atopic eczema, contact eczema, xerotic eczema, seborrhoeic dermatitis, dyshidrosis, discoid eczema, venous eczema, dermatitis herpetiformis, neurodermatitis, and autoeczematization, and statis dermatitis, hidradenitis suppurativa, lichen planus, psoriasis including plaque psoriasis, nail 26NAI-5010499833vlpsoriasis, guttate psoriasis, scalp psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, and psoriatic arthritis, rosacea and scleroderma including morphea.

[0105] In another embodiment, a chronic inflammation comprises a gastrointestinal disorder. A gastrointestinal disorder includes, without limitation, irritable bowel disease, inflammatory bowel disease including Crohn's disease and ulcerative colitis like ulcerative proctitis, left-sided colitis, pancolitis and fulminant colitis.

[0106] In some particular embodiments, the immune-mediated inflammatory disease is Inflammatory Bowel Disease (IBD), Primary Sclerosing Cholangitis (PSC), Takayasu Arteritis, or Ankylosing Spondylitis.

[0107] In another embodiment, a chronic inflammation comprises an infection. An infectious organism can escape the confines of the immediate tissue via the circulatory system or lymphatic system, where it may spread to other parts of the body. If an organism is not contained by the actions of acute inflammation, it may gain access to the lymphatic system via nearby lymph vessels. An infection of the lymph vessels is known as lymphangitis, and infection of a lymph node is known as lymphadenitis. A pathogen can gain access to the bloodstream through lymphatic drainage into the circulatory system. Infections include, without limitation, bacterial cystitis, bacterial encephalitis, pandemic influenza, viral encephalitis, and viral hepatitis (A, B and C). In another embodiment, a chronic inflammation comprises a cardiovascular disease. When LDL cholesterol becomes embedded in arterial walls, it can invoke an immune response. Chronic inflammation eventually can damage the arteries, which can cause them to burst. Cardiovascular disease is any of a number of specific diseases that affect the heart itself and / or the blood vessel system, especially the veins and arteries leading to and from the heart. There are more than 60 types of cardiovascular disorders including, without limitation, a hypertension, endocarditis, myocarditis, heart valve dysfunction, congestive heart failure, myocardial infarction, a diabetic cardiac conditions, blood vessel inflammation like arteritis, phlebitis, vasculitis; arterial occlusive disease like arteriosclerosis and stenosis, inflammatory cardiomegaly, a peripheral arterial disease; an aneurysm; an embolism; a dissection; a pseudoaneurysm; a vascular malformation; a vascular nevus; a thrombosis; a thrombophlebitis; a varicose veins; a stroke. Symptoms of a cardiovascular disorder affecting the heart include, without limitation, chest pain or chest discomfort (angina), pain in one or both arms, the left shoulder, neck, jaw, or back, shortness of breath, dizziness, faster heartbeats, nausea, abnormal heartbeats, feeling fatigued. Symptoms of a cardiovascular disorder affecting the brain include, without limitation, sudden numbness or weakness of the face, arm, or leg, especially on one side of the body, sudden 27NAI-5010499833vlconfusion or trouble speaking or understanding speech, sudden trouble seeing in one or both eyes, sudden dizziness, difficulty walking, or loss of balance or coordination, sudden severe headache with no known cause. Symptoms of a cardiovascular disorder affecting the legs, pelvis and / or arm include, without limitation, claudication, which is a pain, ache, or cramp in the muscles, and cold or numb feeling in the feet or toes, especially at night.

[0108] In another embodiment, a chronic inflammation comprises a cancer. Inflammation orchestrates the microenvironment around tumors, contributing to proliferation, survival, and migration. For example, fibrinous inflammation results from a large increase in vascular permeability which allows fibrin to pass through the blood vessels. If an appropriate procoagulative stimulus is present, such as cancer cells, a fibrinous exudate is deposited. This is commonly seen in serous cavities, where the conversion of fibrinous exudate into a scar can occur between serous membranes, limiting their function. In another example, a cancer is an inflammatory cancer like a NF-KB-driven inflammatory cancer.

[0109] In another embodiment, a chronic inflammation comprises a pharmacologically-induced inflammation. Certain drugs or exogenic chemical compounds are known to affect inflammation. For example, Vitamin A deficiency causes an increase in an inflammatory response.

[0110] In another embodiment, a chronic inflammation comprises an infection. An infectious organism can escape the confines of the immediate tissue via the circulatory system or lymphatic system, where it may spread to other parts of the body. If an organism is not contained by the actions of acute inflammation, it may gain access to the lymphatic system via nearby lymph vessels. An infection of the lymph vessels is known as lymphangitis, and infection of a lymph node is known as lymphadenitis. A pathogen can gain access to the bloodstream through lymphatic drainage into the circulatory system. Infections include, without limitation, bacterial cystitis, bacterial encephalitis, pandemic influenza, viral encephalitis, and viral hepatitis (A, B and C).[OHl] In another embodiment, a chronic inflammation comprises a tissue or organ injury. Tissue or organ injuries include, without limitation, a burn, a laceration, a wound, a puncture, or a trauma.

[0112] In another embodiment, a chronic inflammation comprises a transplant rejection. Transplant rejection occurs when a transplanted organ or tissue is not accepted by the body of the transplant recipient because the immune system of the recipient attacks the transplanted organ or tissue. An adaptive immune response, transplant rejection is mediated through both T cell mediated and humoral immune (antibodies) mechanisms. A transplant rejection can be 28NAI-5010499833vlclassified as a hyperacute rejection, an acute rejection, or a chronic rejection. Chronic rejection of a transplanted organ or tissue is where the rejection is due to a poorly understood chronic inflammatory and immune response against the transplanted tissue. Also included in the term "transplant rejection" is a graft-versus-host disease (GVHD). GVHD is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack. It can also take place in a blood transfusion under certain circumstances. GVHD is divided into acute and chronic forms. Acute and chronic GVHD appear to involve different immune cell subsets, different cytokine profiles, somewhat different host targets, and respond differently to treatment.

[0113] Without wishing to be bound by theory, it has been recently found that ETS2 is a master regulator of inflammatory responses. (See, e.g., Stankey, et al. Nature 630, 447-456 (2024)). ETS2 is an ETS-family transcription factor and proto-oncogene, but its exact role in human macrophages is unclear (See, e.g., Martinez, et al., Front. Oncol. 6, 35 (2016)). However, recently it has been discovered that the ETS2 (gene) is both necessary and sufficient for inflammatory responses in human macrophages, consistent with being a central regulator of effector functions, with dysregulation directly linked to disease, including IBD. In one embodiment, the compounds provided herein, (e.g., Compound 1, Compound 2, Compound 3, and Compound 4) modulate ETS-2 activity. In one embodiment, the compounds provided herein, (e.g., Compound 1, Compound 2, Compound 3, and Compound 4) modulate ETS-2 expression. In one embodiment, the compounds provided herein, (e.g., Compound 1, Compound 2, Compound 3, and Compound 4) downregulate ETS-2-target genes. In one embodiment, the compounds provided herein, (e.g., Compound 1, Compound 2, Compound 3, and Compound 4) abrogate ETS2-driven inflammation in human macrophages. In one embodiment, Compound 1 modulates ETS-2 activity. In one embodiment, Compound 1 modulates ETS-2 expression. In one embodiment, Compound 1 downregulates ETS-2 -target genes. In one embodiment, Compound 1 abrogates ETS2-driven inflammation in human macrophages.

[0114] In one embodiment, a chronic inflammation comprises an ETS-2 mediated inflammation. In one embodiment, a chronic inflammation comprises a macrophage-driven inflammation. In some such embodiments, chronic inflammation is inflammatory bowel disease (IBD).

[0115] In one embodiment, provided herein is a method of blocking ETS2 signalling, the method comprising inhibiting MEK1 / 2 with Compound 1 provided herein.29NAI-5010499833vl

[0116] In one embodiment, provided herein is a method of blocking ETS2 signalling, the method comprising inhibiting MEK1 / 2 with a tablet formulation of Compound 1 provided herein.

[0117] In one embodiment, provided herein is a pharmaceutical composition, such as a tablet formulation, comprising Compound 1 for use in a method of blocking ETS2 signalling in a patient, the method comprising delivering the pharmaceutical composition, to the patient. In certain embodiments, the tablet formulation comprises about 1% to about 10% of (5R,6S)-10, 11 -difluoro- 12-((2 -fluoro-4-iodophenyl)amino)-5,6-dihydroxy -4,5,6, 7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1). In certain embodiments, the tablet formulation further comprises about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

[0118] In one embodiment, provided herein is a method of downregulating ETS2 target genes in a patient having chronic inflammatory disease, the method comprising administering to the patient Compound 1 provided herein.

[0119] In one embodiment, provided herein is a method of downregulating ETS2 target genes in a patient having chronic inflammatory disease, the method comprising administering to the patient a tablet formulation of Compound 1 provided herein.

[0120] In one embodiment, provided herein is a pharmaceutical composition, such as a tablet formulation, comprising Compound 1 for use in a method of downregulating ETS2 signalling in a patient, the method comprising delivering the pharmaceutical composition, to the patient. In certain embodiments, the tablet formulation comprises about 1% to about 10% of (5R,6S)-10,ll -difluoro- 12-((2-fluoro-4-iodophenyl)amino)-5 , 6-dihy droxy-4, 5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1). In certain embodiments, the tablet formulation further comprises about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.30NAI-5010499833vl

[0121] In such embodiments of the methods provided herein, the ETS2 gene pathway is expressed.

[0122] In some such embodiments, Compound 1 or a tablet formulation of Compound 1 provided herein reduces ETS2-dependent functions. In some embodiments, Compound 1 or a tablet formulation of Compound 1 provided herein reduces ETS2-dependent functions selected from cytokine production, phagocytosis, and reactive oxygen species (ROS) generation. In some such embodiments, the reduction of ETS2-dependent function is higher than that of a reference compound. In some such embodiments, the reference compound is a MEK1 / 2 inhibitor selected from mirdametinib (PD-0325901), trametinib, selumetinib, AZD-8330, and PD184352. In one particular embodiment, the reference compound is selumetinib. In one particular embodiment, the reference compound is mirdametinib (PD-0325901).

[0123] In some such embodiments, ETS2-dependent functions include macrophage activation, inflammatory cytokine production, phagocytosis, and / or ROS production.

[0124] In some embodiments, the ETS2-dependent functions are reduced between the range of about 1% to about 5%, about 5% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 25%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, or about 45% to about 50%, relative to the reduction caused by a reference compound. In some such embodiments, the reference compound is a MEK1 / 2 inhibitor selected from mirdametinib (PD-0325901), trametinib, selumetinib, AZD-8330, and PD184352. In one particular embodiment, the reference compound is selumetinib. In one particular embodiment, the reference compound is mirdametinib (PD-0325901).

[0125] In still another embodiment, Compound 1 provided herein has an anti-inflammatory activity capable of modulating cytokines. In an aspect of this embodiment, Compound 1 provided herein has an anti-inflammatory activity capable of reducing the levels of Tumor necrosis factor (TNF), Interleukin-23 (IL-12), Interleukin- ip (IL-ip), or a combination thereof. In other aspects of this embodiment, Compound 1 provided herein has an anti-inflammatory activity capable of reducing the levels of TNF, IL-12, IL-ip, or a combination thereof released from a cell by, e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%. In yet other aspects of this embodiment, Compound 1 provided herein has an anti-inflammatory activity capable of reducing the levels of TNF, IL-12, IL-ip, or a combination thereof released from a cell by, e.g., in a range from, e.g., about 5% to about 100%, about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 31NAI-5010499833vl100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.5. Pharmaceutical Composition

[0126] Provided herein are pharmaceutical compositions. The pharmaceutical compositions provided herein contain therapeutically effective amounts of the compounds provided herein (e.g., Compound 1, Compound 2, Compound 3, and Compound 4) and optionally a pharmaceutically acceptable carrier, diluent, or excipient. In certain embodiments, the pharmaceutical compositions provided herein contain therapeutically effective amounts of Compound 1 provided herein and optionally a pharmaceutically acceptable carrier, diluent, or excipient.

[0127] In some particular embodiments, the pharmaceutical compositions provided herein contain the tablet formulations described herein.

[0128] The compounds provided herein can be formulated into suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administration or in sterile solutions or suspensions for ophthalmic or parenteral administration, as well as transdermal patch preparation and dry powder inhalers. Typically, the compounds provided herein described above are formulated into pharmaceutical compositions using techniques and procedures well known in the art (see, e.g., Ansel Introduction to Pharmaceutical Dosage Forms, Seventh Edition 1999). In one particular embodiment, the compounds provided herein can be formulated into capsules. In some such embodiments, the compounds provided herein are formulated into 2 mg, 4 mg, or 15 mg capsules. In some such embodiments, Compound 1 provided herein is formulated into 2 mg, 4 mg, or 15 mg capsules. In one particular embodiment, Compound 1 provided herein is formulated into 15 mg capsules. In the compositions, effective concentrations of the compounds provided herein are mixed with a suitable pharmaceutical carrier or vehicle. In certain embodiments, the concentrations of the compounds provided herein in the compositions are effective for delivery of an amount, upon administration, that treats, prevents, or ameliorates one or more of the symptoms and / or progression of disorders in a subject, such as inflammatory disease.32NAI-5010499833vl

[0129] Typically, the compositions are formulated for single dosage administration. To formulate a composition, the weight fraction of compound is dissolved, suspended, dispersed, or otherwise mixed in a selected vehicle at an effective concentration such that the treated condition is relieved or ameliorated. Pharmaceutical carriers or vehicles suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of administration.

[0130] The active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. The therapeutically effective concentration may be determined empirically by testing the compounds in in vitro and in vivo systems described herein and then extrapolated therefrom for dosages for humans.

[0131] The concentration of active compound in the pharmaceutical composition will depend on absorption, tissue distribution, inactivation, metabolism and excretion rates of the active compound, the physicochemical characteristics of the compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art. For example, the amount that is delivered is sufficient to ameliorate one or more of the symptoms of disease disclosed herein.

[0132] The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.

[0133] Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.

[0134] Suitable pharmaceutical carriers include inert diluents or fillers, water, and various organic solvents. The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients, and the like. Thus, for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin, and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard-filled gelatin capsules.33NAI-5010499833vlIn one particular embodiment, Compound 1 is administered in a tablet formulation. In some such embodiments, Compound 1 is administered in a tablet formulation as provided herein.

[0135] Preferred materials, therefore, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the active compound therein may be combined with various sweetening or flavoring agents, coloring matters, or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof. Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent, to those skilled in this art. For example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Ester, Pa., 18th Edition (1990).

[0136] In certain embodiments, the effective amount of the compounds in the pharmaceutical composition may be at a level that will exercise the desired effect; for example, about 0.001 mg / kg of a subject’s body weight to about 100 mg / kg of a subject’s body weight in unit dosage for both oral and parenteral administration.

[0137] In one embodiment, a therapeutically effective amount of the compounds or tablet formulation of Compound 1 provided herein generally is in the range of about 0.001 mg / kg / day to about 100 mg / kg / day. In aspects of this embodiment, an effective amount of the compounds or tablet formulation of Compound 1 provided herein may be, e.g., at least 0.001 mg / kg / day, at least 0.01 mg / kg / day, at least 0.1 mg / kg / day, at least 1.0 mg / kg / day, at least 5.0 mg / kg / day, at least 10 mg / kg / day, at least 15 mg / kg / day, at least 20 mg / kg / day, at least 25 mg / kg / day, at least 30 mg / kg / day, at least 35 mg / kg / day, at least 40 mg / kg / day, at least 45 mg / kg / day, or at least 50 mg / kg / day. In other aspects of this embodiment, an effective amount of the compounds or tablet formulation of Compound 1 provided herein may be in the range of, e.g., about 0.001 mg / kg / day to about 10 mg / kg / day, about 0.001 mg / kg / day to about 15 mg / kg / day, about 0.001 mg / kg / day to about 20 mg / kg / day, about 0.001 mg / kg / day to about 25 mg / kg / day, about 0.001 mg / kg / day to about 30 mg / kg / day, about 0.001 mg / kg / day to about 35 mg / kg / day, about 0.001 mg / kg / day to about 40 mg / kg / day, about 0.001 mg / kg / day to about 45 mg / kg / day, about 0.001 mg / kg / day to about 50 mg / kg / day, about 0.001 mg / kg / day to about 75 mg / kg / day, or about 0.001 mg / kg / day to about 100 mg / kg / day. In yet other aspects of this embodiment, an effective amount of the compounds or tablet formulation of Compound 1 provided herein may be in the range of, e.g., about 0.01 mg / kg / day to about 10 mg / kg / day, about 0.01 mg / kg / day to about 15 mg / kg / day, about 0.01 mg / kg / day to about 20 mg / kg / day, about 0.01 mg / kg / day to about 25 mg / kg / day, about 0.01 mg / kg / day to about 30 mg / kg / day, about 0.01 mg / kg / day to 34NAI-5010499833vlabout 35 mg / kg / day, about 0.01 mg / kg / day to about 40 mg / kg / day, about 0.01 mg / kg / day to about 45 mg / kg / day, about 0.01 mg / kg / day to about 50 mg / kg / day, about 0.01 mg / kg / day to about 75 mg / kg / day, or about 0.01 mg / kg / day to about 100 mg / kg / day. In still other aspects of this embodiment, an effective amount of the compounds or tablet formulation of Compound 1 provided herein may be in the range of, e.g., about 0.1 mg / kg / day to about 10 mg / kg / day, about 0.1 mg / kg / day to about 15 mg / kg / day, about 0.1 mg / kg / day to about 20 mg / kg / day, about 0.1 mg / kg / day to about 25 mg / kg / day, about 0.1 mg / kg / day to about 30 mg / kg / day, about 0.1 mg / kg / day to about 35 mg / kg / day, about 0.1 mg / kg / day to about 40 mg / kg / day, about 0.1 mg / kg / day to about 45 mg / kg / day, about 0.1 mg / kg / day to about 50 mg / kg / day, about 0.1 mg / kg / day to about 75 mg / kg / day, or about 0.1 mg / kg / day to about 100 mg / kg / day.

[0138] In other aspects of this embodiment, an effective amount of the compounds or tablet formulation of Compound 1 provided herein may be in the range of, e.g., about 1 mg / kg / day to about 10 mg / kg / day, about 1 mg / kg / day to about 15 mg / kg / day, about 1 mg / kg / day to about 20 mg / kg / day, about 1 mg / kg / day to about 25 mg / kg / day, about 1 mg / kg / day to about 30 mg / kg / day, about 1 mg / kg / day to about 35 mg / kg / day, about 1 mg / kg / day to about 40 mg / kg / day, about 1 mg / kg / day to about 45 mg / kg / day, about 1 mg / kg / day to about 50 mg / kg / day, about 1 mg / kg / day to about 75 mg / kg / day, or about 1 mg / kg / day to about 100 mg / kg / day. In yet other aspects of this embodiment, an effective amount of the compounds provided herein may be in the range of, e.g., about 5 mg / kg / day to about 10 mg / kg / day, about 5 mg / kg / day to about 15 mg / kg / day, about 5 mg / kg / day to about 20 mg / kg / day, about 5 mg / kg / day to about 25 mg / kg / day, about 5 mg / kg / day to about 30 mg / kg / day, about 5 mg / kg / day to about 35 mg / kg / day, about 5 mg / kg / day to about 40 mg / kg / day, about 5 mg / kg / day to about 45 mg / kg / day, about 5 mg / kg / day to about 50 mg / kg / day, about 5 mg / kg / day to about 75 mg / kg / day, or about 5 mg / kg / day to about 100 mg / kg / day.

[0139] The dose of the compounds provided herein to be administered to a subject is rather widely variable and can be subject to the judgment of a health-care practitioner. In any given case, the amount of the compounds administered will depend on such factors as the solubility of the active component, the formulation used and the route of administration. In one embodiment, application of a topical concentration provides intracellular exposures or concentrations of about 0.01 - 10 pM.

[0140] The administered dose can also be expressed in units other than mg / kg / day. For example, doses for parenteral administration can be expressed as mg / m2 / day. One of ordinary skill in the art would readily know how to convert doses from mg / kg / day to mg / m2 / day given35NAI-5010499833vleither the height or weight of a subject or both. For example, a dose of 1 mg / kg / day for a 65 kg human is approximately equal to 38 mg / m2 / day.

[0141] In some embodiments, an effective dose of the compounds or a tablet formulation of Compound 1 provided herein can be administered once daily (QD or qd) or divided into multiple daily. In addition, the administration can be continuous (i.e., daily for consecutive days or every day), intermittent, e.g., in cycles (i.e., including days, weeks, or months of rest without drug). Cycling therapy can reduce the development of resistance, avoid or reduce the side effects, and / or improve the efficacy of the treatment.

[0142] As used herein, the term “daily” is intended to mean that a therapeutic compound is administered once or more than once each day, for example, for a period of time.

[0143] In one embodiment, the pharmaceutical composition of the compounds or tablet formulation of Compound 1 provided herein is administered in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or greater than 40 cycles. In certain embodiments, the pharmaceutical composition of the compounds or tablet formulation of Compound 1 provided herein is administered for 1 to 25 cycles. In one embodiment, the median number of cycles administered in a group of patients is about 1. In one embodiment, the median number of cycles administered in a group of patients is about 2. In one embodiment, the median number of cycles administered in a group of patients is about 3. In one embodiment, the median number of cycles administered in a group of patients is about 4.

[0144] In certain embodiments, treatment cycles comprise multiple doses of the pharmaceutical composition of the compounds provided herein is administered to a patient in need thereof over multiple days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or greater than 14 days), optionally followed by treatment dosing holidays (e.g, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or greater than 28 days).

[0145] In certain embodiments, the pharmaceutical composition of the compounds provided herein are administered in one or more 28-day cycles in the methods described herein. In certain embodiments, the pharmaceutical composition of the compounds provided herein are administered in a 28-day cycle in the methods described herein.

[0146] In certain embodiments, the pharmaceutical composition of the compounds provided herein are administered orally in the methods described herein. In certain embodiments, the pharmaceutical composition of the compounds provided herein is administered with food or without food. In another embodiment, the pharmaceutical composition of the compounds36NAI-5010499833vlprovided herein is dispersed in water or juice (e.g., apple juice or orange juice) and administered orally as a suspension.

[0147] In one embodiment, the compounds provided herein can also be administered intradermally, intramuscularly, intraperitoneally, percutaneously, intravenously, subcutaneously, intranasally, epidurally, sublingually, intracerebrally, intravaginally, transdermally, rectally, mucosally, by inhalation, or topically to the ears, nose, eyes, or skin. The mode of administration is left to the discretion of the healthcare practitioner and can depend in part upon the site of the medical condition.

[0148] The compounds disclosed herein may be administered as a sole therapy. The compounds disclosed herein may also be administered in combination with another therapy or therapies. In some embodiments, the compounds disclosed herein may also be administered in combination with another pharmaceutical agent with activity against diseases or disorders in which the ETS2 pathway is downregulated, such as chronic inflammation or an immune-mediated inflammatory disease or their symptoms.

[0149] Other therapies include, but are not limited to, administration of other therapeutic agents, radiation therapy, or both.

[0150] In instances where the compound described herein is administered with other therapeutic agents, the compound described herein need not be administered in the same pharmaceutical composition as other therapeutic agents, and may be because of different physical and chemical characteristics, be administered by a different route. For example, the compound or composition may be administered orally to generate and maintain good blood levels thereof, while the other therapeutic agent may be administered intravenously. The determination of the mode of administration and the advisability of administration, where possible, in the same pharmaceutical composition, is well within the knowledge of the skilled clinician. The initial administration can be made according to established protocols known in the art, and then, based upon the observed effects, the dosage, modes of administration and times of administration can be modified by the skilled clinician. The particular choice of compound (and where appropriate, other therapeutic agent and / or radiation) will depend upon the diagnosis of the attending physicians and their judgment of the condition of the patient and the appropriate treatment protocol. Other therapeutic agents may include chemotherapeutic agents, such as anti -tumor substances. Such conjoint treatment may be achieved by way of the simultaneous, sequential, or separate dosing of the individual components of treatment.

[0151] In another embodiment, upon administration to an individual, the pharmaceutical composition of the compounds provided herein is delivered to a macrophage. Macrophages 37NAI-5010499833vlare one of the key cell types believed to be involved in the control of the inflammation response. The resultant high level of a therapeutic compound having anti-inflammatory activity present in the macrophages results in a clinically effective treatment of chronic inflammation. In an aspect of this embodiment, upon administration to an individual, a therapeutically effective amount of the pharmaceutical composition of the compounds provided herein is preferentially delivered to a macrophage. In other aspects of this embodiment, upon administration to an individual, a therapeutically effective amount of the pharmaceutical composition of the compounds provided herein is substantially delivered to a macrophage. In yet other aspect of this embodiment, upon administration to an individual, the amount of a therapeutically effective amount of the pharmaceutical composition of the compounds provided herein delivered to a macrophage is, e.g., at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% of the total amount of the compounds contained in the administered pharmaceutical composition. In still other aspects of this embodiment, upon administration to an individual, the amount of the compounds of the pharmaceutical composition disclosed herein delivered to a macrophage is in a range of, e.g., about 5% to about 100%, about 10% to about 100%, about 15% to about 100%, about 20% to about 100%, about 25% to about 100%, about 30% to about 100%, about 35% to about 100%, about 40% to about 100%, about 45% to about 100%, about 50% to about 100%, about 5% to about 90%, about 10% to about 90%, about 15% to about 90%, about 20% to about 90%, about 25% to about 90%, about 30% to about 90%, about 35% to about 90%, about 40% to about 90%, about 45% to about 90%, about 50% to about 90%, about 5% to about 80%, about 10% to about 80%, about 15% to about 80%, about 20% to about 80%, about 25% to about 80%, about 30% to about 80%, about 35% to about 80%, about 40% to about 80%, about 45% to about 80%, about 50% to about 80%, about 5% to about 70%, about 10% to about 70%, about 15% to about 70%, about 20% to about 70%, about 25% to about 70%, about 30% to about 70%, about 35% to about 70%, about 40% to about 70%, about 45% to about 70%, or about 50% to about 70% of the total amount of the compounds contained in the administered pharmaceutical composition.

[0152] The examples described below are intended to be merely exemplary, and those skilled in the art will recognize, or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific compounds, materials, and procedures. All such equivalents are considered to be within the scope of the claimed subject matter and are encompassed by the appended claims.38NAI-5010499833vlEXAMPLES

[0153] The following examples show that Compound 1 consistently outperformed the FDA-approved MEK inhibitor selumetinib across all tested doses, showing greater downregulation of ETS2 target genes, as well as experimentally validated MEK1 / 2 pathway genes. These data suggest more robust and durable MEK inhibition by Compound 1 under inflammatory conditions.Example 1: Monocyte Purification and Macrophage Differentiation

[0154] Leukocyte apheresis cones (n = 5) were obtained from healthy donors by NHS Blood and Transplant (Tooting Blood Donor Centre) under ethical approval from the London - Brent Regional Ethics Committee (REC: 21 / LO / 0682). Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation (Histopaque 1077, Sigma) and monocytes were positively selected using CD 14 Microbeads (Miltenyi Biotec). Macrophage differentiation was performed using conditions that model chronic inflammation (TPP): 3 days Granulocyte-macrophage colony-stimulating factor (GM-CSF) (50ng / ml, Peprotech) followed by 3 days GM-CSF, Tumor Necrosis Factor Alpha (TNFoc) (50ng / ml, Peprotech), prostaglandin E2 (PGE2) (Ipg / ml, Sigma Aldrich), and Pam3CysSerLys4 (PamsCSK ) (Ipg / ml, Invivogen). All cultures were performed at 37°C, 5% CO2 in antibiotic-free RPMI1640 media containing 10% FBS, GlutaMAX, and MEM Non-Essential Amino Acids (all ThermoFisher). On day 4 of culture, 1 pl of Compound 1, selumetinib (Selleckchem) or vehicle (DMSO) were added to a final drug concentration of 0.01 pM, 0.1 pM or 1 pM. On day 6, cells were detached using Accutase (Biolegend) and harvested, and supernatants were snap frozen. RNA was extracted from macrophage lysates (AllPrep DNA / RNA Micro Kit, Qiagen) and sequencing libraries prepared from 10 ng RNA using the SMARTer Stranded Total RNA-Seq Kit v2 Pico Input Mammalian (Takara) following the manufacturer’s instructions. Libraries were sequenced on NovaSeq (lOObp, PE reads).Example 2: RNA Sequencing Analysis

[0155] FASTQ files were pre-processed using MultiQC. Reads were trimmed using Trim Galore (Phred score 24) and filtered to remove reads < 20bp. Ribosomal reads (mapping to Human ribosomal DNA complete repeating unit, GenBank: U13369.1) were removed using BBSplit (sourceforge.net / projects / bbmap / ). Reads were aligned to the human genome (hg38) using HISAT2 and converted to BAM files, sorted, and indexed using SAMtools. Gene read counts were obtained with the featureCounts program from Rsubread using the GTF annotation39NAI-5010499833vlfile for GRCh38 (version 102). Differential expression analysis was performed in R using limma with voom transformation and including donor as a covariate. For Gene Set Variance Analysis (GSVA) (using the gsva package in R), quantile normalized cpm values were used for expression values and lists of positive ETS2 targets (genes significantly downregulated in TPP macrophages following deletion of the chr21q22 enhancer or following ETS2 editing) and direct MEK1 / 2 targets (genes significantly downregulated following treatment of TPP macrophages with PD-0325901) were obtained from Stankey, et al. Nature 630, 447-456 (2024). A spreadsheet containing the gene lists used for the GSVA is provided in Exhibit A. GSEA was performed using the fGSEA package in R. Gene sets were either obtained from Gene Ontology Biological Pathways (downloaded from MSigDB) or experimentally-derived based on differential expression analysis of selumetinib or Compound 1 (1 pM) versus vehicle control. Statistical significance was calculated using the adaptive multilevel split Monte Carlo method. See FIG. 2, FIG. 3, and FIGS. 4A-4C.Example 3: Cytokine quantification

[0156] Supernatant cytokine concentrations were quantified in duplicate using the LegendPLEX Human Inflammation Panel (Biolegend) according to the manufacturer’s instructions. Data was collected by flow cytometry (BD LSR FortessaTM X-20).Example 4: Results

[0157] Using the protocols of Examples 1-3 above, the ability of Compound 1 and selumetinib to abrogate ETS2-driven inflammatory responses were tested in primary human macrophages, cultured in conditions that have been shown to mimic chronic inflammation. In brief, one of three doses of each drug (0.01 pM, 0.1 pM and 1 pM, or a vehicle control) were added on day 4 of a six-day culture protocol (see Examples above), after which the cells were harvested and supernatants frozen for subsequent analysis.

[0158] Using RNA-sequencing and Gene Set Variance Analysis (see Examples above), it was shown that Compound 1 led to greater downregulation of ETS2 target genes than selumetinib at every dose tested. This result was consistent with the known relationship between MEK1 / 2 and ETS2 and with the observation that Compound 1 downregulated experimentally validated MEK1 / 2 targets more than selumetinib at every dose. See FIGS.5A-5C

[0159] Genes were identified that were significantly downregulated by Compound 1 or selumetinib at the highest dose used for each (1 pM). The identified genes were then used as40NAI-5010499833vlgene sets in a Gene Set Enrichment Analysis to determine how enriched each drug’s effects were in the spectrum of changes that occur in inflammatory macrophages following CRISPR-editing of ETS2. It was observed that while the gene sets from both drugs were enriched in ETS2 knockout macrophages, the enrichment of Compound 1 was significantly greater -evidenced by a larger normalized enrichment score (-3.96 versus -3.56) and greater significance (1.2 x IO'250versus 3.7 x 10'74). See FIGS. 6A and 6B. In addition, all of the individual macrophage inflammation pathways previously shown to require ETS2 (including macrophage activation, inflammatory cytokine production, phagocytosis, and ROS production) were significantly downregulated by Compound 1. See FIG. 7. Comparison of secreted cytokine levels in cell culture supernatants showed donor variability, with no significant differences between Compound 1 and selumetinib. See FIGS. 8A-8L.

[0160] Collectively, these data demonstrate the following:• Superior and stronger suppression of ETS2 signalling. At all doses, Compound 1 showed greater downregulation of ETS2-regulated genes compared to selumetinib.• Superior inhibition of macrophage inflammatory pathways. Compared to selumetinib, Compound 1 provides superior inhibition of macrophage inflammatory pathways mediated by ETS2 which have been shown to play a central role in the pathogenesis of multiple immune-mediated inflammatory diseases (including, e.g., Inflammatory Bowel Disease (IBD), Primary Sclerosing Cholangitis (PSC), Takayasu Arteritis, or Ankylosing Spondylitis).• Suppression of core macrophage functions. Compound 1 significantly reduced ETS2-dependent functions such as cytokine production, phagocytosis, and reactive oxygen species (ROS) generation, all known to be central to chronic inflammation.• Deeper mechanistic engagement. Gene Set Enrichment Analysis revealed that Compound l’s effects more closely mirrored ETS2 knockout profiles, with a higher normalized enrichment score (-3.96 vs -3.56) and greater statistical significance (1.2 x 10-25°vs3 7xIO74) as compared to selumetinib.

[0161] The embodiments provided herein are not to be limited in scope by the specific embodiments provided in the examples which are intended as illustrations of a few aspects of the provided embodiments and any embodiments that are functionally equivalent are encompassed by the present disclosure. Indeed, various modifications of the embodiments provided herein are in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.41NAI-5010499833vl

[0162] A number of references have been cited, the disclosures of which are incorporated herein by reference in their entirety.42NAI-5010499833vl

Claims

CLAIMSWhat is claimed:

1. A method of treating chronic inflammation or inflammatory disease, comprising administering a therapeutically effective amount of (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), to a patient having chronic inflammation or inflammatory disease, wherein the structure of Compound 1 is:

2. A method of treating chronic inflammation or inflammatory disease, comprising administering to a patient having chronic inflammation or chronic inflammatory disease a tablet formulation comprising about 1% to about 10% of (5R,6S)-10, 11 -difluoro- 12-((2-flu oro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

3. A method of blocking ETS2 signalling, the method comprising inhibiting MEK1 / 2 with the compound of claim 1.

4. A method of blocking ETS2 signalling, the method comprising inhibiting MEK1 / 2 with the tablet formulation of claim 2.43NAI-5010499833vl5. A method of downregulating ETS2 target genes in a patient having chronic inflammatory disease, the method comprising administering to the patient the compound of claim 1.

6. A method of downregulating ETS2 target genes in a patient having chronic inflammatory disease, the method comprising administering to the patient the tablet formulation of claim 2.

7. The method of any one of claims 1 to 6, wherein the solid form comprises a free base of Compound 1.

8. The method of any one of claims 1 to 7, wherein the solid form is characterized by an XRPD pattern comprising peaks at approximately 8.5, 9.2, 12.0, 15.1, 17.0, 18.3, 20.8, 22.0, 24.1, and 27.4° 20.

9. The method of any one of claims 1 to 8, wherein the ETS2 gene pathway is expressed.

10. A method of treating a patient with immune-mediated inflammatory disease, comprising administering a therapeutically effective amount of the Compound 1 or the tablet formulation of Compound 1 to the patient having immune-mediated inflammatory disease.

11. The method of claim 10, wherein the immune-mediated inflammatory disease is Inflammatory Bowel Disease (IBD), Primary Sclerosing Cholangitis (PSC), Takayasu Arteritis, or Ankylosing Spondylitis.

12. The method of any one of claims 1 to 11, wherein Compound 1 exhibits a reduction of ETS2-dependent functions selected from cytokine production, phagocytosis, and reactive oxygen species (ROS) generation.

13. The method of claim 12, wherein the reduction of ETS2-dependent function is higher than that of a reference compound.

14. The method of claim 13, wherein the reference compound is selumetinib.

15. The method of any one of claims 1 to 14, wherein Compound 1 is administered as a tablet formulation having a weight of 1 mg, 4 mg, or 10 mg.44NAI-5010499833vl